

Aaron Tward, MD, PhD, completed his MD-PhD at the University of California-San Francisco, then completed his residency in Otolaryngology-Head and Neck Surgery at Harvard Medical School. He then completed his clinical fellowship in Neurotology at Massachusetts Eye and Ear Infirmary/Massachusetts General Hospital. During residency and fellowship, he performed post-doctoral research at the Broad Institute of MIT and Harvard Medical School. He subsequently returned to UCSF where he remains on faculty as an Associate Professor of Otolaryngology-Head and Neck Surgery. His clinical practice focuses on the care of patients with disorders of the ear and skull base. His basic science academic research interests include the genetics and genomics of cancer, stem cell biology, and developmental biology.

In addition to his academic pursuits, Aaron is actively engaged in developing gene therapies for otologic indications and other conditions. He served as the Chief Scientific Officer of Akouos, Inc. (Acquired by Eli Lilly) and he currently serves as Associate Vice President of Gene Therapy at Eli Lilly. In addition, he is the scientific co-founder of Affinia Therapeutics.